---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016061"
form_type: "8-K"
ticker: null
cik: "0001300734"
company_name: "SHINECO, INC."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:24:35.745496+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shineco closes 51% acquisition of InfiniClone for ~$19.9M cash and 3.45M shares

## Summary
- Acquired 51% equity in InfiniClone Limited from Dr. Lim Kah Meng.
- Consideration: $19,895,600 cash plus 3,450,000 shares of common stock.
- Shares issued under Regulation S; seller represented non-U.S. person status.
- Financial statements and pro forma data to be filed within 71 days.

## SEC filing metadata
- accession: 0001641172-25-016061
- form_type: 8-K
- cik: 0001300734
- company_name: SHINECO, INC.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1300734/000164117225016061/0001641172-25-016061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1300734/000164117225016061/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016061
- JSON: https://secwatch.observer/filing/0001641172-25-016061.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016061.txt

## Key facts
- M&A Transactions
  SHINECO, INC. completed an acquisition involving Dr. Lim Kah Meng for US$19,895,600 in cash and 3,450,000 shares (closed 2025-06-18).
  - Action: acquisition
  - Counterparty: Dr. Lim Kah Meng
  - Consideration: US$19,895,600 in cash and 3,450,000 shares
  - Closing: 2025-06-18
  source text: in InfiniClone to Shineco Life Science; therefore, InfiniClone became a direct subsidiary of Shineco Life Science. In exchange, Shineco Life Science paid to the Seller US$19,895,600 in cash and the Company issued 3,450,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”). The Shares were issued in reliance on Rule 902 of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1300734/000164117225016061/0001641172-25-016061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.